TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 43, 2013, Pages 17426-17431

  Rachakonda, P Sivaramakrishna ^a   Hosen, Ismail ^a   De Verdier, Petra J ^b,c   Fallah, Mahdi ^a   Heidenreich, Barbara ^a   Ryk, Charlotta ^b,c   Wiklund, N Peter ^b,c   Steineck, Gunnar ^c,d   Schadendorf, Dirk ^e   Hemminki, Kari ^a,f   Kumar, Rajiv ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f LUND UNIVERSITY   (Sweden)

Author keywords

Cancer genetics; Noncoding mutations; Reporter assays; TERT mutations; Transcription factors

Indexed keywords

E TWENTY SIX TRANSCRIPTION FACTOR; PROTEIN P53; TELOMERASE REVERSE TRANSCRIPTASE; TERNARY COMPLEX FACTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; BINDING SITE; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TRANSITIONAL CELL CARCINOMA;

CANCER GENETICS; NONCODING MUTATIONS; REPORTER ASSAYS; TERT MUTATIONS; TRANSCRIPTION FACTORS;

AGED, 80 AND OVER; BASE SEQUENCE; CARCINOMA, TRANSITIONAL CELL; CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LUCIFERASES; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM RECURRENCE, LOCAL; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROPORTIONAL HAZARDS MODELS; TELOMERASE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84886390673     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1310522110     Document Type: Article

References (40)

1. Dwyer J, Li H, Xu D, Liu JP (2007) Transcriptional regulation of telomerase activity: Roles of the the Ets transcription factor family. Ann N Y Acad Sci 1114:36-47.
2. Daniel M, Peek GW, Tollefsbol TO (2012) Regulation of the human catalytic subunit of telomerase (hTERT). Gene 498(2):135-146.
3. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144(5):646-674.
4. Kyo S, Takakura M, Fujiwara T, Inoue M (2008) Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Sci 99(8): 1528-1538.
5. Stein GS, Montecino M, van Wijnen AJ, Stein JL, Lian JB (2000) Nuclear structure-gene expression interrelationships: Implications for aberrant gene expression in cancer. Cancer Res 60(8):2067-2076.
6. Renaud S, et al. (2007) Dual role of DNA methylation inside and outside of CTCFbinding regions in the transcriptional regulation of the telomerase hTERT gene. Nucleic Acids Res 35(4):1245-1256.
7. Horn S, et al. (2013) TERT promoter mutations in familial and sporadic melanoma. Science 339(6122):959-961.
8. Wei GH, et al. (2010) Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo. EMBO J 29(13):2147-2160.
9. Patton EE, Harrington L (2013) Cancer: Trouble upstream. Nature 495(7441):320-321.
10. Huang FW, et al. (2013) Highly recurrent TERT promoter mutations in human melanoma. Science 339(6122):957-959.
11. Killela PJ, et al. (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 110(15):6021-6026.
12. Burger M, et al. (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63(2):234-241.
13. Cohen SM, Shirai T, Steineck G (2000) Epidemiology and etiology of premalignant and malignant urothelial changes. Scand J Urol Nephrol Suppl (205):105-115.
14. Anastasiadis A, et al. (2012) Follow-up procedures for non-muscle-invasive bladder cancer: An update. Expert Rev Anticancer Ther 12(9):1229-1241.
15. Wu XR (2005) Urothelial tumorigenesis: A tale of divergent pathways. Nat Rev Cancer 5(9):713-725.
16. Cheng L, et al. (2011) Bladder cancer: Translating molecular genetic insights into clinical practice. Hum Pathol 42(4):455-481.
17. Gschwind A, Fischer OM, Ullrich A (2004) The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat Rev Cancer 4(5):361-370.
18. Kuball J, et al. (2002) Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J Clin Oncol 20(4): 957-965.
19. Dulak AM, et al. (2013) Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 45(5):478-486.
20. Hahn WC, et al. (1999) Creation of human tumour cells with defined genetic elements. Nature 400(6743):464-468.
21. Thilly WG (2003) Have environmental mutagens caused oncomutations in people? Nat Genet 34(3):255-259.
22. Prasad SM, Decastro GJ, Steinberg GD; Medscape (2011) Urothelial carcinoma of the bladder: Definition, treatment and future efforts. Nat Rev Urol 8(11):631-642.
23. Joudi FN, Smith BJ, O'Donnell MA; National BCG-Interferon Phase 2 Investigator Group (2006) Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer. Urol Oncol 24(4):344-348.
24. Logan C, Brown M, Hayne D (2012) Intravesical therapies for bladder cancer - Indications and limitations. BJU Int 110(Suppl 4):12-21.
25. Xu D, Dwyer J, Li H, Duan W, Liu JP (2008) Ets2 maintains hTERT gene expression and breast cancer cell proliferation by interacting with c-Myc. J Biol Chem 283(35): 23567-23580.
26. Hsu CP, Hsu NY, Lee LW, Ko JL (2006) Ets2 binding site single nucleotide polymorphism at the hTERT gene promoter - Effect on telomerase expression and telomere length maintenance in non-small cell lung cancer. Eur J Cancer 42(10): 1466-1474.
27. Savage SA, et al. (2007) Genetic variation in five genes important in telomere biology and risk for breast cancer. Br J Cancer 97(6):832-836.
28. Varadi V, et al. (2009) A functional promoter polymorphism in the TERT gene does not affect inherited susceptibility to breast cancer. Cancer Genet Cytogenet 190(2): 71-74.
29. Beesley J, et al.; kConFab Investigators; Australian Ovarian Cancer Study Group; ABCTB Investigators; Ovarian Cancer Association Consortium (2011) Functional polymorphisms in the TERT promoter are associated with risk of serous epithelial ovarian and breast cancers. PLoS ONE 6(9):e24987.
30. Kote-Jarai Z, et al.; COGS-CRUK GWAS-ELLIPSE (Part of GAME-ON) Initiative; UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; PRACTICAL Consortium (2013) Fine-mapping identifies multiple prostate cancer risk loci at 5p15, one of which associates with TERT expression. Hum Mol Genet 22(12):2520-2528.
31. Abecasis GR, et al.; 1000 Genomes Project Consortium (2012) An integrated map of genetic variation from 1,092 human genomes. Nature 491(7422):56-65.
32. Bojesen SE, et al. (2013) Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet 45(4): 371-384.
33. Xu D, et al. (2000) Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. Oncogene 19(45):5123-5133.
34. Ruden M, Puri N (2013) Novel anticancer therapeutics targeting telomerase. Cancer Treat Rev 39(5):444-456.
35. Mukherjee S, Firpo EJ, Wang Y, Roberts JM (2011) Separation of telomerase functions by reverse genetics. Proc Natl Acad Sci USA 108(50):E1363-E1371.
36. Vogelstein B, et al. (2013) Cancer genome landscapes. Science 339(6127):1546-1558.
37. Hall RR, Prout GR (1990) Staging of bladder cancer: Is the tumor, node, metastasis system adequate? Semin Oncol 17(5):517-523.
38. Reuter VE, Epstein JI, Amin MB, Mostofi FK (1999) The "WHO/ISUP Consensus Classification of Urothelial (Transitional Cell) Neoplasms": Continued discussion. Hum Pathol 30(7):879-880.
39. Ryk C, et al. (2005) Influence of GSTM1, GSTT1, GSTP1 and NAT2 genotypes on the p53 mutational spectrum in bladder tumours. Int J Cancer 113(5):761-768.
40. Berggren P, et al. (2001) p53 mutations in urinary bladder cancer. Br J Cancer 84(11): 1505-1511.